News and Trends 5 Dec 2022
Positive antibody persistence for vaccine treating mosquito disease
A single shot vaccine for mosquito-borne disease chikungunya has had positive antibody persistence data 12 months after vaccination. The primary…
Valneva
- Latest Posts
News and Trends 26 Oct 2021
Valneva’s Inactivated Covid-19 Vaccine Aces Phase III Trial
Last week, the French vaccine maker Valneva announced promising phase III trial results of its inactivated Covid-19 vaccine: a well-established…
News and Trends 19 Aug 2021
Chikungunya Vaccine First to Succeed in Phase III Trial
In a significant step in the fight against tropical disease, the mosquito-borne viral disease chikungunya may become preventable with a…
News and Trends 10 Jun 2021
The Top European Biotech Investment Rounds in May
Last month saw huge biotech investment rounds dedicated to Covid-19 vaccines in Europe, including IPOs by Valneva and Vaccitech. However,…
ADVERTISEMENT
News and Trends 7 May 2020
Lyme Disease Vaccine Gets Pfizer’s Backing in €284M Deal
The French biotech Valneva will collaborate with Pfizer to develop and commercialize Valneva’s phase II-stage Lyme disease vaccine candidate. The…
News and Trends 18 Nov 2019
Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I
Update (18/11/2019): French biotech Valneva has revealed additional phase I results concerning its experimental chikungunya vaccine; all 68 patients that…
Interview 4 Sep 2019
Overcoming Clinical Setbacks to Fight Insect-Borne Diseases
Sometimes things don’t go your way in the biotech industry. The CEO of Valneva, Thomas Lingelbach, shared his experience of…
More News! 20 Nov 2018
Phase I Gives Hope for First Zika Vaccine
Results from a Phase I trial showed promising safety and efficacy of a potential first vaccine against the mosquito-borne Zika…
News and Trends 12 Dec 2016
French Biotech Puts a New Lyme Disease Vaccine on the Horizon
There is currently no vaccine for the fast-growing disease in the US, & treatments cost over $1Bn every year. Valneva…
News and Trends 28 Aug 2015
[Update] Valneva’s duck stem cells attract two new Vaccine-deals
French Valneva continues to sign license agreements for its duck derived stem cell line that produces novel vaccines. Lyon-based Valneva was…
ADVERTISEMENT
News and Trends 18 Mar 2015
Valneva penetrates Chinese Market thanks to a license agreement
A few months ago, the article "An Anglo-French Partnership To Cure Hepatitis B" related Valneva partnerships with Immune Targeting Systems.…
News and Trends 31 Jan 2015
An Anglo-French Partnership To Cure Hepatitis B
European biotechnology company Valneva and UK company Immune Targeting Systems (ITS) announced that they have signed an exclusive worldwide commercial…